Skip to content
Search

Latest Stories

NPA demands ‘tougher regulation’ on online sale of weight loss jabs

NPA weight loss jab regulations
Mounjaro injections (Photo by Sandy Huffaker for The Washington Post via Getty Images)

Online sellers should be required to prescribe weight loss jabs only after conducting a full two-way consultation, including careful consideration of a patient’s medical history

The National Pharmacy Association (NPA), representing independent community pharmacies, has called for tougher regulation of the online sale of weight loss jabs to protect patients amid a prediction of a new year’s boom in demand.

The association argues that current regulation “leaves the door open for medicines to be supplied without appropriate patient consultation and access to patient records.”


It has urged the General Pharmaceutical Council (GPhC) to require greater consultation with patients before dispensing weight loss jabs and other high-risk medication online.

The association stressed that online sellers should not just rely on information provided in online questionnaires but also gather important historical medical information before a full two-way consultation between prescriber and patient.

Draft guidelines on weight loss medication 

The GPhC proposed changes to their current guidance for online pharmacies to improve patient safety. It launched a consultation on the revised guidance on 17 September, inviting feedback until 9 October 2024 from the public, carers, pharmacists, pharmacy technicians, other healthcare professionals, and pharmacy owners.

In its response to proposed guidelines on prescribing weight loss medication, the NPA highlighted critical gaps, stating that proposed safeguards “still leaves the door open for medicines to be prescribed/supplied without appropriate two-way direct patient consultation and access to patient records for a full clinical picture particularly where high-risk medicines are involved, and the risk to patient safety remains”.

“We [the NPA] suggest including an expectation that a prescriber should have a two-way dialogue with the patient so that the patient can make an informed choice about potential treatment options particularly where high-risk medicines (for example, weight-loss medicines) are being prescribed.”

NPA chair Nick Kaye described obesity as one of the biggest challenges facing the country and emphasised the role pharmacies play in helping patients lose and maintain a healthy weight.

He acknowledged the benefits of weight loss injections in tackling obesity when “prescribed as part of a carefully managed treatment programme for patients who are most in need of support.”

However, he expressed concern that the current regulations allow some patients to “inappropriately access” weight loss injections without proper consultation or examination of historical medical records.

“There’s nothing wrong with online services in principle, but it’s important the regulator takes this opportunity to make compulsory a full consultation before dispensing high-risk medication such as weight loss injections and ensure supply is prioritised for those in most clinical need, including those with type two diabetes.”

Kaye further emphasised the importance of treating medicines with care, noting, “Medicines are not like ordinary goods for sale, they must be handled with great care because they have the power to harm as well as to heal.”

Those who are unsure about medicine are advised to speak to their pharmacist for advice.

Rising demand and safety concerns

The NPA’s call for action comes amid warnings of a boom in demand for weight loss treatments this year, as the government plans to expand the rollout of Mounjaro (tirzepatide) injections over the next few years.

Many pharmacies dispense weight loss medication or offer injectable medicines as part of private weight loss programmes.

The NPA reiterated that the best practice is to prescribe weight loss medications following a full conversation with a patient, whether virtually or in person, often as part of a programme to make long-term lifestyle changes.

It also warned patients to avoid buying weight loss injections from unregulated online sellers, who may be selling dangerous fake counterfeit medications.

The Medicines and Healthcare Regulatory Agency (MHRA) also cautioned patients not to purchase medicines from unregulated suppliers such as beauty salons and via social media.

Risks of misuse

The NPA has warned that improper prescribing of weight loss injections can put some patients, including those with a history of eating disorders or those outside the licensed BMI categories and have low BMIs, at greater risk of severe adverse effects.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less